Semaglutide Biosimilar & Generic Market Emerging Trends and Long-Term Forecast 2026 to 2035

AI Briefing

• – Semaglutide Injectable Generic (Subcutaneous) market expected to grow at a CAGR of 14.4% from 2023 to 2035 due to increasing demand for affordable diabetes treatment options.
• – Rising adoption of biosimilars and generics in the EU and US markets, driven by regulatory approvals and reduced patent expirations.
• – Emergence of new semaglutide biosimilar and generic formulations, including oral tablets and injectables, to capitalize on the growing demand for innovative diabetes management solutions.